This success was further enhanced when combined with immune checkpoint inhibitors, leading to pronounced effects in animal models. The research driving InProTher's work leverages the expertise of Associate Professor Peter Johannes Holst and his team, as well as international collaborators.
The company has recently received a significant boost through a €6.00M Seed Round investment on 24 May 2023, with funding from The European Innovation Council and SeedFolio. InProTher's focus on leveraging pre-clinical success and its collaboration with renowned experts make it a compelling prospect in the biotechnology and healthcare industries.
InProTher
InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst.
Founded 2018
2-10 employees
Seed
Total: $8.50M
Biotechnology, Health Care
General Information
Company Name
InProTher
Founded Year
2018
Employees
2-10
Industries
Biotechnology, Health Care
Funding Stage
Seed
Social
BounceWatch is an independent company data service, not affiliated with InProTher. To contact InProTher, visit inprother.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does InProTher compare?
A PDF of InProTher and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting InProTher soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is InProTher on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
About InProTher
Business keywords: Cancer immunotherapy, Pre-clinical models, Advanced therapies, Immune checkpoint inhibitors, Tumor immunity, Research collaboration, Cancer therapy development, Immunotherapy success, Professor Holst, Associate Professor Holst, Cancer research, Cancer treatment innovations
Funding Rounds & Investors (3)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Seed Round | €6.00M | 2 |
|
24 May 2023 |
| Grant | €2.50M | 1 |
|
15 Oct 2021 |
| Venture Round | Undisclosed | 1 |
|
16 Jun 2021 |
InProTher Alternatives & Competitors
View All Alternatives
InProTher vs
ImmunOs Therapeutics AG
Switzerland
Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific role in inn...
Series B
15 employees
Biotechnology, Health Care
InProTher vs
Imugene Limited
Australia
Bringing Effective New Treatments And Options To Patients Who Need Them
IPO
26 employees
Biotechnology, Health Care
InProTher vs
Alloplex Biotherapeutics Inc
United States
A robust cellular therapeutic platform for treating cancer.
Series A
5 employees
Biopharma, Biotechnology
FAQ About InProTher
InProTher is creating advanced cancer immunotherapies based on pre-clinical models with Professor Holst.
InProTher was founded in 2018.
InProTher operates in Biotechnology and Health Care. Its work centres on Cancer immunotherapy, Pre-clinical models, Advanced therapies and Immune checkpoint inhibitors.
InProTher has approximately 2-10 employees.
InProTher has completed 3 funding rounds, raising a total of $8.50M. The latest funding stage is Seed.
Top alternatives and competitors to InProTher include ImmunOs Therapeutics AG, Imugene Limited, Alloplex Biotherapeutics Inc, Trillium Therapeutics Inc., Inceptor Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
InProTher and ImmunOs Therapeutics AG are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for InProTher, https://bouncewatch.com/company/inprother, updated 11 September 2024. When citing, please name BounceWatch and link this page.
